International Patent: DSRNA CONJUGATE FOR SIMULTANEOUSLY INHIBITING EXPRESSION OF C3 AND C5 GENES AND USE OF DSRNA CONJUGATE

GENEVA, July 9 -- LEADERNA THERAPEUTICS, LTD. filed a patent application (CN2025/147423) for “DSRNA CONJUGATE FOR SIMULTANEOUSLY INHIBITING EXPRESSION OF C3 AND C5 GENES AND USE OF DSRNA CONJUGATE”. With publication no. WO/2026/145589, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: A61K 31/713

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....